There is a growing population of people doing serious investigative work outside conventional scientific and medical institutions. Not hobbyists. Not health influencers. People running structured self-experiments with crossover designs and washout periods. People using AI to synthesize hundreds of papers in an afternoon on questions their physicians never had time to investigate. People ordering their own bloodwork through direct-to-consumer laboratories, tracking biomarkers across months, and designing interventions around what they find. Communities of patients with the same rare condition coordinating protocols, pooling data, and producing observations that fall outside funded research priorities.
They are not waiting for permission.
A decade ago, most of this required expertise, access, money, or institutional support that few individuals possessed. The literature was locked behind paywalls. Statistical analysis required training. Experimental design required a methods course. Laboratory work required a laboratory. AI has collapsed most of those barriers. Wearables and direct diagnostics have collapsed others. What remains is not a capability problem.
Capability alone does not create a functioning ecosystem. A person who can interrogate the literature and design a self-experiment still needs somewhere to go with what they find. They need ways to coordinate, to verify, to pool results, to identify bad work, to earn the trust of strangers. That infrastructure does not exist yet.
The Resource Wasn’t Enough
In the 1860s, petroleum went from a curiosity to an economic force inside a few years. Production exploded. Independent operators entered from every direction. Anyone with a lease and a drill could pull crude out of the ground.
Extracting oil was only the beginning. The industry needed refining, transportation, storage, finance, distribution, and standards. The resource was abundant. The infrastructure around it was scarce.
John D. Rockefeller built Standard Oil into the dominant force in American petroleum, but not by owning more oil than anyone else. Standard Oil’s power emerged in refining, purchasing, and above all, transportation. Economic historians have argued that the difficult-to-enter stage of the petroleum industry was not production but the route to market. Standard’s position was magnified by its control over scarce complementary infrastructure. If you could not move your oil economically, it did not matter how much of it you had.
The oil did not have to belong to Rockefeller. The route did.
That dependence became visible in 1879, when the Tidewater Pipeline gave independent refiners a long-distance route that bypassed the railroad transportation arrangements on which Standard’s position partly depended. When everyone must travel through the incumbent route, route control looks like domain ownership. A new route reveals what was actually owned.
The Missing Infrastructure
What is the equivalent of refining, pipelines, transport, and distribution for citizen science?
Citizen science needs ways to find other people investigating the same problem. To coordinate protocols and design experiments that produce comparable data. To verify that a protocol was actually followed. To pool results and reproduce findings. To identify bad work before it spreads. To track safety problems. To establish that a laboratory or assay provider is reliable. To build individual and community reputation. To fund promising work. To preserve data with provenance intact. To turn useful observations into evidence that strangers have reason to trust.
None of this is another chatbot. What is missing is the infrastructure around the investigators: the refining, transport, and distribution layer that turns raw capability into a functioning scientific ecosystem.
The opportunity is not more intelligence. It is the route to market.
Why Medical Infrastructure Became Institutional
Rockefeller’s fortune came from oil, but his philanthropy reshaped American medicine using the same strategic logic. Frederick T. Gates, Rockefeller’s principal architect for philanthropy, had practical operating experience in large-scale integrated industrial operations, including Rockefeller’s Lake Superior iron enterprise, before he shaped medical philanthropy. When he drafted the governing logic for Rockefeller’s higher-education giving, his own retrospective summary was plain: “The key word was the word system.”
Gates surveyed whole fields and identified strategic centers rather than scattering capital. He concentrated resources in selected institutions, attached conditions to grants, and used exemplary institutions to reshape the broader system.
In medicine, Rockefeller capital strengthened selected institutions that conformed to standards influenced by the Flexner Report and earlier reform efforts. Johns Hopkins became the strategic model. Full-time clinical faculty, university control, stronger laboratories, hospital affiliation. The General Education Board distributed approximately $94 million to twenty-five medical schools between 1913 and 1929. The funding was tied to institutional requirements. Gates expected capital to secure institutional change.
The resulting system produced extraordinary real advances in biomedical research, laboratory medicine, pharmacology, clinical training, and research methodology. Scientific medicine deserved much of the authority it accumulated.
The institutional infrastructure that carried those advances also concentrated control. For more than a century, serious medical knowledge became tightly coupled to institutional systems. If you wanted your work to count, you generally traveled through someone else’s infrastructure. Their journals. Their credentials. Their accreditation. Their funding. Their licensing boards.
Citizen scientists are not entering an empty field. They are routing around infrastructure built during an earlier technological era.
Where the Institutional Advantage Is Weakening
Scientific attention has always been scarce, rationed by career incentives and funding structures. AI can direct enormous amounts of investigative attention toward questions that institutions have no economic or reputational reason to pursue. Neglected diseases. Individual biological variation. Off-patent compounds. Interactions unlikely to attract a conventional trial.
Randomized controlled trials establish average treatment effects across a population. They are far less equipped to answer what will happen to a specific individual with a specific biology under specific conditions. An individual who can design a crossover experiment, measure outcomes with wearables and laboratory tests, and analyze results with AI can investigate a question conventional research is poorly structured to answer for them.
A person lives inside their biology continuously. Institutions see episodes. Measurement and interpretation are increasingly moving toward the individual: wearables, home testing, direct-to-consumer laboratory services, remote monitoring.
Contract laboratories, automated systems, open-source liquid handlers, and remote laboratory access are reducing the capital required for certain wet-lab tasks. NSF recently announced a $400 million investment in a national network of AI-enabled autonomous laboratory test beds.
Institutional medicine still holds substantial advantages in expensive physical experiments, complex manufacturing, high-risk interventions, large-scale safety surveillance, some regulatory processes, and broad legitimacy.
The Infrastructure Market
Citizen scientists need systems that make good work recognizable.
How does someone outside an institution establish that they are competent? That the work happened as described? That the data are real? That the protocol was followed? That the result can be reproduced? That conflicts are visible, adverse events are reported, and a laboratory is reliable? That a community has earned a reputation worth trusting?
Historically, institutions solved much of this problem by proxy. Credentials, journals, licensing, universities, hospitals, and professional organizations told strangers whom to trust. A medical degree, a publication in a peer-reviewed journal, a hospital affiliation. These are legitimacy shortcuts. They work partly because establishing legitimacy directly has always been expensive.
Institutional infrastructure exists in large part because legitimacy has historically been expensive to establish directly.
If legitimacy can be established directly, the institutions that once supplied it become optional.
Provenance systems. Independent assay and quality-control networks. Reputation architectures that let strangers verify competence without credentials. The resource is abundant and growing. The route to market is unbuilt.
The Lesson Worth Keeping
Citizen science is now producing a new abundance. Capability. Scientific attention. Data. Investigators. Communities. The resource is real and it is spreading.
The infrastructure that would let those investigators coordinate, verify, trust, and build on each other’s work barely exists. Someone will build it.